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Abstract
Purpose Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy.
Methods As part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3 + 3 dose-escalation design), 
we determined the maximum tolerated dose (MTD) of afatinib with carboplatin (A/C) or with carboplatin plus paclitaxel 
(A/C/P). Starting doses: afatinib 20 mg/day, carboplatin AUC6 (A/C) with paclitaxel 175 mg/m2 (A/C/P) (chemotherapy: 
Day 1 of 21-day cycles). The primary objective was to determine the MTDs; safety, pharmacokinetics and antitumor activ-
ity were also evaluated.
Results Thirty-eight patients received A/C (n = 12) or A/C/P (n = 26). No dose-limiting toxicities (DLTs) were reported with 
A(20 mg)/C(AUC6). One patient experienced DLT in the A(40 mg)/C(AUC6) cohort (grade 3 acneiform rash); A(40 mg)/
C(AUC6) was determined as the recommended phase II dose (RP2D) for A/C. Two patients each had DLTs with A(20 mg/
day)/C(AUC6)/P(175 mg/m2): fatigue, infection, diarrhea, small intestine hemorrhage, dehydration, renal impairment, 
neutropenic sepsis (n = 1), mucositis (n = 1); A(40 mg)/C(AUC5)/P(175 mg/m2): febrile neutropenia (n = 1), mucositis, 
fatigue (n = 1); and A(30 mg)/C(AUC5)/P(175 mg/m2): stomatitis (n = 1), mucositis (n = 1). No DLT was observed with 
A(20 mg)/C(AUC5)/P(175 mg/m2), determined as the RP2D for A/C/P. The most frequent drug-related adverse events were 
(A/C; A/C/P): rash (75%; 73%), fatigue (67%; 69%), and diarrhea (58%; 88%). Drug plasma concentrations were similar 
between cycles, suggesting no drug–drug interactions. Objective response rates in these heavily pretreated patients were 
A/C, 3/12 (25%); A/C/P, 5/26 (19%).
Conclusions Afatinib 40 mg/day (approved monotherapy dose) with carboplatin AUC6, and afatinib 20 mg/day with car-
boplatin AUC5 and paclitaxel 175 mg/m2 demonstrated manageable safety and antitumor activity. Afatinib > 20 mg/day in 
the triple combination was not well tolerated.
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Introduction
Afatinib is an irreversible ErbB family blocker, which 
binds covalently to the intracellular kinase domains of, 
and prevents signaling from, all kinase-active members of 
the ErbB family. It is, therefore, active against epidermal 
growth factor receptor (EGFR), human epidermal growth 
factor receptor 2 (HER2) and ErbB4, and indirectly inhibits 
transphosphorylation of the kinase-inactive ErbB3 [1]. As a 
single agent, afatinib is approved for the first-line treatment 
of advanced EGFR mutation-positive lung adenocarcinoma, 
having demonstrated improved progression-free survival 
(PFS) versus platinum-based chemotherapy in these patients 
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[2, 3]. In addition, afatinib was recently approved for the 
treatment of patients unselected for EGFR mutations with 
advanced squamous cell carcinoma of the lung following 
first-line chemotherapy, with activity superior to erlotinib 
in this setting [4].
Given their non-overlapping mechanisms of action, the 
addition of targeted therapies such as afatinib to existing 
chemotherapy regimens may improve outcomes in patients 
with advanced solid tumors. In vitro cell-based assays have 
shown greater efficacy with afatinib combined with pacli-
taxel than with single-agent treatment [5]. The combination 
of afatinib with paclitaxel or docetaxel in xenograft animal 
models has also demonstrated improved efficacy compared 
with single-agent therapy [6].
The clinical feasibility and tolerability of combining 
afatinib with paclitaxel, and with paclitaxel plus bevaci-
zumab, were previously explored in earlier parts of this trial 
(a total of four drug combinations were assessed in patients 
with advanced solid tumors in this trial [NCT00809133]) 
[5, 7]. Both of these earlier combination regimens demon-
strated manageable safety profiles and antitumor activity at 
the maximum tolerated doses (MTDs). Here, we evaluated 
the combination of afatinib with carboplatin, and with carbo-
platin and paclitaxel, in patients with advanced solid tumors.
Materials and methods
Patients
Patients eligible for treatment had advanced, non-resect-
able and/or metastatic solid tumors suitable for treatment 
with either carboplatin or carboplatin and paclitaxel, and 
were recruited at two centers in the United Kingdom. Key 
eligibility criteria included age ≥ 18 years; Eastern Coop-
erative Oncology Group performance status (ECOG PS) of 
0 or 1; life expectancy of at least 3 months and adequate 
organ function (cardiac left ventricular function with 
resting ejection fraction [LVEF] ≥ 50%; absolute neutro-
phil count ≥ 1.5 × 109/L [> 2.0 × 109/L for patients allo-
cated to carboplatin]; platelets ≥ 100,000/µL; total biliru-
bin ≤ 26 µmol/L; aspartate aminotransferase and/or alanine 
aminotransferase ≤ 2.5 times the upper limit of normal; cre-
atinine ≤ 132 µmol/L and creatinine clearance > 60 mL/min 
by Cockcroft–Gault equation).
Exclusion criteria included gastrointestinal tract disease 
that could impair drug absorption; significant cardiovas-
cular disease; active infectious disease; known interstitial 
lung disease; untreated or symptomatic brain metastases; 
persistent grade ≥ 2 neuropathy or neurotoxicity from any 
cause; and treatment with chemotherapy, immunotherapy, 
radiotherapy, biologic therapy, hormone therapy, EGFR- or 
HER2-targeting drugs or other investigational drugs within 
4 weeks prior to starting trial medication.
The study was conducted in accordance with the Dec-
laration of Helsinki and Good Clinical Practice, and ethi-
cal approval was provided by the UK Integrated Research 
Application System. All patients provided written informed 
consent.
Study design and treatment
A phase I open-label trial assessed four different drug 
combinations using a 3 + 3 dose-escalation design 
(NCT00809133); previous analyses of other combination 
regimens included in the trial have been reported [5, 7]. 
In this report, afatinib was evaluated in combination with 
carboplatin (A/C) or carboplatin plus paclitaxel (A/C/P). 
In both combinations, oral afatinib was administered once 
daily, beginning on Day 2 of Cycle 1 in 21-day cycles, at 
a starting dose of 20 mg/day, and escalated to 40 mg (the 
approved monotherapy starting dose) and then 50 mg in 
subsequent dose cohorts. Chemotherapy was administered 
intravenously on Day 1 of each 21-day cycle: carboplatin at 
a dose targeting an area under the concentration–time curve 
of 6 mg/mL.min (AUC6), and paclitaxel at 175 mg/m2 (car-
boplatin was administered after paclitaxel, consistent with 
standard medical practice in the United Kingdom) [8]. Tar-
get doses for carboplatin were calculated using the Calvert 
formula (dose [mg] = target AUC [mg/mL.min] × (glomeru-
lar filtration rate [GFR; mL/min] + 25 mL/min)). Based on 
the American Society for Clinical Oncology guidelines, the 
GFR used in the Calvert formula was capped at 125 mL/min 
[9]. In the event of toxicity with carboplatin AUC6, a dose 
reduction to AUC5 was allowed. Patients continued combi-
nation treatment for six cycles or until tumor progression, 
intolerable adverse events (AEs) or withdrawal of consent. 
Patients with clinical benefit after six cycles could continue 
either with combination treatment or single-agent afatinib.
The primary endpoint was safety, assessed as dose-
limiting toxicities (DLTs) to define the MTD of the two 
afatinib–chemotherapy combinations. MTD was defined as 
the highest dose of afatinib in combination with carboplatin, 
or with carboplatin and paclitaxel, at which no more than 
one of six patients experienced a DLT during Cycle 1. To be 
evaluable for determination of the MTD, patients must have 
completed the first 2 weeks of therapy or have experienced a 
DLT; patients who did not meet either of these criteria were 
replaced within the respective dose cohort. Secondary end-
points included pharmacokinetic parameters and antitumor 
activity (objective tumor responses [OR]).
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Assessments
All patients were assessed for AEs according to the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI CTCAE, version 3.0); relation-
ship to study treatment was assessed by the investigators.
DLTs were defined as any of the following drug-
related AEs: grade 4 uncomplicated neutropenia (i.e., 
fever ≤ 38.3 °C) for > 7 days; neutropenia associated with 
fever > 38.5 °C; platelets < 25 × 109/L or grade 3 thrombo-
cytopenia associated with bleeding requiring transfusion; 
grade ≥ 2 decrease in LVEF; uncontrolled hypertension 
despite multiple anti-hypertension therapies; grade ≥ 2 
worsening of renal function; grade > 2 diarrhea despite 
anti-diarrheal treatment; persistent grade ≥ 2 diarrhea 
for ≥ 7 days despite supportive care; grade > 2 nausea 
and/or vomiting despite antiemetic treatment; persistent 
grade ≥ 2 vomiting for ≥ 7 days despite supportive care; 
and all other non-hematologic toxicities of grade ≥ 3, 
except incompletely treated nausea, vomiting or diarrhea.
For the assessment of pharmacokinetic parameters of 
afatinib (AUC τ,ss and Cmax,ss), total platinum (AUC 0−24 
and Cmax) and paclitaxel (AUC 0−23 and Cmax), blood was 
collected on Days 1 and 2 of Cycles 1 and 2. Samples 
were taken pre- and post- (1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0 
and 24.0 h) carboplatin infusion (in the A/C arm) and pre- 
and post- (1.0, 2.0, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 8.0, 9.0 and 
24.0 h) paclitaxel infusion (in the A/C/P arm). Of note, 
the 1.0- and 2.0-h time points post-paclitaxel infusion 
were conducted only during Cycle 2. A sample was also 
collected on Day 15 of Cycle 1 before the administration 
of afatinib in both treatment combinations. Plasma con-
centrations of afatinib and paclitaxel were analyzed by a 
validated high-performance liquid chromatography–tan-
dem mass spectrometry method at Boehringer Ingelheim 
(Biberach, Germany) and Nuvisan GmbH (Neu-Ulm, 
Germany), respectively. Concentrations of total plati-
num (from carboplatin) were determined by a validated 
inductively coupled plasma/mass spectrometry assay at 
Nuvisan GmbH (Neu-Ulm, Germany).
Tumor assessments were performed by the investi-
gators at screening and every 6 weeks after the start of 
treatment until progressive disease (PD) according to 
Response Evaluation Criteria in Solid Tumors (RECIST, 
version 1.0).
Statistical analysis
AEs and antitumor activity were assessed in all patients 
who received at least one dose of afatinib. All analyses in 
this trial were descriptive and exploratory.
Results
Patients and treatment exposure
Thirty-eight patients were treated in the trial, with the most 
common tumor type (A/C, 58%; A/C/P, 65%) being non-
small cell lung cancer (NSCLC). Additional baseline demo-
graphics and disease characteristics are shown in Table 1. 
Twelve patients received the combination of A/C and 26 
received A/C/P. In the A/C arm, 10 (83%) patients completed 
at least one cycle and 6 (50%) patients completed at least six 
cycles of treatment; all patients discontinued study treatment 
due to PD. In the A/C/P arm, 24 (92%) patients completed 
at least one cycle and 11 (42%) patients completed at least 
six cycles of treatment. The primary reason for termination 
of study treatment in the A/C/P arm was PD in 21 patients 
(81%) and AEs, including DLTs, in 5 patients (19%). Median 
treatment duration was 106 days (range 13–390) for A/C and 
85 days (range 6–401) for A/C/P.
MTD assessment
In the A/C arm, nine patients were evaluable for the deter-
mination of MTD (Fig. 1a; Table 2). In Cohort 1 (afatinib 
20 mg plus carboplatin AUC6), three patients received com-
bination treatment and no DLTs were reported. In Cohort 
2 (afatinib 40 mg plus carboplatin AUC6), no DLTs were 
reported in the first three evaluable patients (two patients 
were not evaluable for MTD determination and were 
replaced), and the cohort was expanded to nine patients 
(one patient was not evaluable and was replaced). Of the six 
patients who were evaluable for MTD in Cohort 2, one expe-
rienced a DLT (grade 3 acneiform rash). The afatinib dose, 
here combined with a dose of carboplatin, was not further 
escalated from the standard monotherapy dose of 40 mg, 
consistent with standard of care. Afatinib 40 mg plus carbo-
platin AUC6 was defined as the recommended phase II dose 
(RP2D) in the A/C arm, without an MTD being reached.
In the A/C/P arm, 23 of 26 patients were evalu-
able for assessment of the MTD (Fig. 1b; Table 2). Of 
the seven patients who received treatment in Cohort 1 
(afatinib 20 mg plus carboplatin AUC6 plus paclitaxel 
175 mg/m2), six were evaluable for MTD and two had 
DLTs, which included grade 3 neutropenic sepsis with 
Clostridium difficile diarrhea in one patient and grade 
3 mucositis in the other patient (Table 2). The carbopl-
atin dose was decreased to AUC5 in Cohort 2 (afatinib 
20 mg plus carboplatin AUC5 plus paclitaxel 175 mg/m2), 
in which three patients received treatment and no DLTs 
were reported. The afatinib dose was then increased to 
40 mg in Cohort 3 (afatinib 40 mg plus carboplatin AUC5 
plus paclitaxel 175 mg/m2), and five patients received 
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treatment and were evaluable for MTD; two patients 
had DLTs (grade 3 fatigue and grade 3 mucositis in one 
patient; grade 3 febrile neutropenia in another). Owing 
to the DLTs observed, an intermediate afatinib dose of 
30 mg was explored in Cohort 4 (afatinib 30 mg plus car-
boplatin AUC5 plus paclitaxel 175 mg/m2). Eight patients 
received this treatment and, of the six patients evaluable 
for MTD, two reported DLTs (grade 3 stomatitis; grade 
3 mucositis). The next lower dose level (afatinib 20 mg 
plus carboplatin AUC5 plus paclitaxel 175 mg/m2) was 
then expanded with three patients, in addition to the three 
patients already treated with these doses in Cohort 2, and 
no DLTs were reported. Thus, afatinib 20 mg was identi-
fied as the MTD in combination with carboplatin AUC5 
and paclitaxel 175 mg/m2. This dose was also identified 
as the RP2D for the A/C/P combination.
Adverse events
The most frequent drug-related AEs of any grade in the A/C 
arm were rash (grouped term; n = 9, 75%), which was most 
commonly acneiform, fatigue (n = 8, 67%) and diarrhea 
(n = 7, 58%). Most AEs were of CTCAE grade 1 or 2 in 
intensity (Table 3), and the only non-hematologic treatment-
related grade 3 AEs in this arm were rash, fatigue and diar-
rhea (one patient each; 8%). There were no treatment-related 
grade ≥ 4 AEs.
The most frequent drug-related AEs in the A/C/P arm 
were diarrhea (n = 23, 88%), rash (grouped term; n = 19, 
73%) and fatigue (n = 18, 69%). Most AEs were of CTCAE 
grade 1 or 2 in intensity, and there were no grade ≥ 4 
treatment-related AEs (Table 4). The most common non-
hematologic treatment-related grade 3 AEs in this arm 
Table 1  Patient demographics 
at baseline
A/C afatinib plus carboplatin, A/C/P afatinib plus carboplatin plus paclitaxel, ECOG PS Eastern Coopera-
tive Oncology Group performance status; NSCLC non-small cell lung cancer
a ECOG PS declined between screening and baseline; baseline visit was 2 days after the screening visit for 
this patient
b Esophageal (n = 1) and ovarian cancer (n = 1) in the A/C arm, adrenal (n = 1), biliary tree (n = 1), bladder 
(n = 1) and endometrial cancer (n = 1) in the A/C/P arm
A/C (n = 12) A/C/P (n = 26)
Age, years
 Median (range) 57.5 (35–80) 60.5 (26–73)
Gender, n (%)
 Male 8 (67) 13 (50)
 Female 4 (33) 13 (50)
Race, n (%)
 White 8 (67) 23 (88)
 Black 2 (17) 1 (4)
 Asian 2 (17) 2 (8)
ECOG PS, n (%)
 0 0 2 (8)
 1 12 (100) 23 (88)
 2 0 1 (4)a
Time from first histologic diagnosis, years
 Median (range) 1.5 (0.7–6.3) 1.9 (0.7–6.6)
Tumor type, n (%)
 NSCLC 7 (58) 17 (65)
 Pancreas 1 (8) 3 (12)
 Gastrointestinal tract 2 (17) 0
 Breast 0 2 (8)
 Otherb 2 (17) 4 (15)
Patients with previous anti-cancer therapy, n (%)
 Surgery 5 (42) 11 (42)
 Systemic chemotherapy 12 (100) 26 (100)
 Immunotherapy 1 (8) 1 (4)
 Hormone therapy 0 (0) 1 (4)
 Radiotherapy 6 (50) 13 (50)
 Other (including biologic therapy) 7 (58) 6 (23)
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were mucositis (n = 4; 15%) and fatigue (n = 3; 12%). Seven 
(27%) patients, including one patient with Clostridium dif-
ficile infection and one patient with mucositis (discussed 
above as DLTs), had AEs leading to discontinuation of study 
treatment.
Pharmacokinetics
Table 5 summarizes key pharmacokinetic parameters for 
the RP2D cohorts of both treatment arms. Total platinum 
and paclitaxel showed a comparable exposure, based on 
Cmax and AUC, in the absence and presence of afatinib, 
suggesting no clinically relevant effect of afatinib on 
the pharmacokinetic parameters of these drugs. Afatinib 
reached peak plasma concentration 1–4 h after administra-
tion in the A/C arm and 3–8 h after administration in the 
A/C/P arm.
Antitumor activity
In the A/C arm, three patients (25%) had a confirmed partial 
response (PR), five (42%) had stable disease (SD) and one 
(8%) had PD; three patients (25%) were not evaluable for 
tumor response. Five patients (42%) achieved disease control 
(PR or SD) for at least 6 months. No ORs were seen in the 
seven patients with NSCLC receiving A/C treatment, but 
four patients (57%) had a best response of SD, one (14%) for 
at least 6 months. A response duration of 10.2 months was 
seen in one patient with a gastrointestinal neuroendocrine 
tumor.
In the A/C/P arm, five patients (19%) had a confirmed 
PR, eleven (42%) had SD and six (23%) had PD; four 
patients (15%) were not evaluable for tumor response. 
Of the 17 patients with NSCLC treated with A/C/P, ORs 
were reported for three patients (18%), and eight (47%) 
had SD. Four patients (15%), all of whom had NSCLC, 
achieved disease control (PR or SD) for at least 6 months. 
A response duration of 10.5 months was seen in one patient 
with NSCLC.
Discussion
In this phase I study, we assessed the safety and prelimi-
nary antitumor activity of afatinib in combination with car-
boplatin, and with carboplatin plus paclitaxel. In the A/C 
Fig. 1  Dose-escalation schema 
and incidence of DLTs in the 
A/C arm (a) and the A/C/P 
arm (b). A20 + C6, afatinib 20 
mg/day + carboplatin AUC6; 
A40 + C6, afatinib 40 mg/day 
+ carboplatin AUC6; A20 + 
P175 + C5, afatinib 20 mg/
day + paclitaxel 175 mg/m2 
+ carboplatin AUC5; A20 + 
P175 + C6, afatinib 20 mg/
day + paclitaxel 175 mg/m2 
+ carboplatin AUC6; A30 + 
P175 + C5, afatinib 30 mg/
day + paclitaxel 175 mg/m2 
+ carboplatin AUC5; A40 + 
P175 + C5, afatinib 40 mg/
day + paclitaxel 175 mg/m2 + 
carboplatin AUC5
a
b
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arm, dose escalation was not continued beyond afatinib 
40 mg/day plus carboplatin AUC6 and so an MTD was 
not reached. The standard dose for afatinib monotherapy is 
40 mg/day [10, 11]. Since manageable safety and antitumor 
activity were observed at this dose level with carboplatin 
AUC6, and no drug–drug interactions were observed, the 
RP2D was determined as afatinib 40 mg plus carbopl-
atin AUC6. In the A/C/P arm, the MTD and RP2D were 
determined to be afatinib 20 mg plus carboplatin AUC5 
plus paclitaxel 175 mg/m2. For this triplet combination, 
the afatinib single-agent dose needed to be de-escalated 
(from 40 to 20 mg) for the regimen to be tolerated. In both 
treatment combinations, afatinib at the RP2D was associ-
ated with a manageable safety profile. The most common 
drug-related AEs were rash, fatigue and diarrhea, and the 
majority of these were grade 1 or 2 in intensity. The AE 
profiles of the combinations were in line with the known 
individual safety profiles of afatinib, carboplatin and pacli-
taxel [5, 10, 12‒12].
Afatinib pharmacokinetic parameters were consistent 
with earlier studies of afatinib as a single agent [13, 14] and 
in combination [7], suggesting carboplatin and paclitaxel 
did not influence absorption and plasma concentrations of 
afatinib. Similarly, total platinum (from carboplatin) and 
paclitaxel plasma concentrations were similar in the absence 
and presence of afatinib, suggesting there were no relevant 
interactions between afatinib and paclitaxel and/or carbopl-
atin in this study.
Evidence of antitumor activity was observed with both 
the A/C and A/C/P combinations. A/C was associated with 
disease control (PR or SD) in eight patients (67%), while 
disease control was observed in 16 patients (62%) receiv-
ing A/C/P. In this study, 58% and 65% of patients in the 
A/C and A/C/P arms, respectively, had NSCLC. Of these 
pretreated NSCLC patients, more than half in each treat-
ment combination had disease control (57% in the A/C arm 
and 65% in the A/C/P arm), with 18% achieving an OR 
in the A/C/P arm. Of note, a response in one patient with 
Table 2  DLTs (related to study drug) in Cycle 1 by dose cohort
A/C afatinib plus carboplatin, A/C/P afatinib plus carboplatin plus paclitaxel, AUC5 area under the concentration–time curve of 5 mg/mL min, 
AUC6 area under the concentration–time curve of 6 mg/mL min, DLT dose-limiting toxicity, MTD maximum tolerated dose
a Preferred term: dermatitis acneiform
b Preferred term: mucosal inflammation
c Clostridium difficile
d Includes one patient with febrile neutropenia and one patient with neutropenic sepsis
A/C A/C/P
A (20 mg) + C 
(AUC6) (n = 3)
A (40 mg) + C 
(AUC6) (n = 9)
A (20 mg) + C 
(AUC6) + P 
(175 mg/m2) (n = 7)
A (20 mg) + C 
(AUC5) + P 
(175 mg/m2) (n = 6)
A (40 mg) + C 
(AUC5) + P 
(175 mg/m2) (n = 5)
A (30 mg) + C 
(AUC5) + P (175 mg/
m2) (n = 8)
Patients evaluable 
for MTD
3 6 6 6 5 6
Patients with a DLT 0 1 2 0 2 2
DLTs leading to 
permanent discon-
tinuation of study 
treatment
0 0 2 0 0 0
DLTs, n
 Acneiform  rasha 0 1 0 0 0 0
 Mucositisb 0 0 1 0 1 1
 Fatigue 0 0 1 0 1 0
 Infection 0 0 1 0 0 0
 Dehydration 0 0 1 0 0 0
 Diarrhea 0 0 1 0 0 0
 Febrile neutrope-
nia/neutropenic 
 sepsisd
0 0 1 0 1 0
 Renal impairment 0 0 1 0 0 0
 Small intestinal 
hemorrhage
0 0 1 0 0 0
 Stomatitis 0 0 0 0 0 1
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NSCLC in the A/C/P combination arm was maintained for 
10.5 months.
Several randomized trials have evaluated the poten-
tial clinical activity of the combination of EGFR-targeted 
agents with chemotherapy in advanced cancers, particularly 
NSCLC. Phase III studies in the first-line NSCLC setting 
in populations unselected for EGFR mutation have shown 
varying degrees of clinical efficacy for EGFR-targeted 
agent–chemotherapy combinations versus chemotherapy 
alone [15‒17]. In the phase III TRIBUTE trial, 1059 
treatment-naïve patients with NSCLC were randomized to 
first-line carboplatin and paclitaxel combined with either 
erlotinib or placebo. No survival benefit was observed with 
erlotinib plus chemotherapy versus placebo plus chemother-
apy in the overall trial population; however, a substantial 
prolongation of survival was observed in the ‘never smoked’ 
subgroup (22.5 vs 10.1 months; hazard ratio [HR] 0.49, 95% 
confidence interval [CI] 0.28–0.85; p = 0.01) [15]. Similarly, 
in the phase III TALENT trial, 1172 treatment-naïve patients 
with NSCLC were randomized to first-line gemcitabine 
and cisplatin combined with either erlotinib or placebo, 
with no survival benefit observed in the erlotinib group. In 
a small subgroup of patients who ‘never smoked’, overall 
survival (OS) and PFS were increased with chemotherapy 
and erlotinib, compared to chemotherapy alone [16]. In 
contrast to the TALENT and TRIBUTE studies, the phase 
III FAST-ACT2 trial, conducted primarily in Asia, dem-
onstrated significantly improved PFS (HR 0.57, 95% CI 
0.47–0.69; p < 0.0001) and OS (HR 0.79, 95% CI 0.64–0.99; 
p = 0.0420) with first-line chemotherapy (gemcitabine and 
platinum; Days 1 and 8 of a 4-week cycle) plus erlotinib 
(Days 15–28 of each cycle) over chemotherapy alone in 451 
treatment-naïve patients with NSCLC. Benefit was primar-
ily shown in those with EGFR mutation-positive disease; 
however, tumor samples were available in only 53% of the 
intent-to-treat population [17].
The combination of EGFR-targeted agents with chem-
otherapy has also been explored in the relapsed/refrac-
tory NSCLC setting. A randomized, phase II study in 165 
patients with non-squamous NSCLC previously treated with 
one prior platinum-based chemotherapy regimen showed 
that pemetrexed plus erlotinib significantly improved PFS, 
OS and time to treatment failure versus pemetrexed alone; 
however, the combination was associated with an increase 
in grade 3/4 AEs [18]. We have previously reported on the 
combination of afatinib and weekly paclitaxel in patients 
with advanced solid tumors [5]. This regimen has since 
been assessed in a phase III trial of patients with relapsed/
Table 3  Treatment-related AEs 
in at least 10% of total patients 
in the A/C arm
A/C afatinib plus carboplatin, AE adverse event, AUC6 area under the concentration–time curve of 6 mg/
mL min
+ Grouped term (rash included reported preferred terms of folliculitis, cellulitis, dermatitis acneiform and 
rash; nausea/vomiting included reported preferred terms of nausea and vomiting)
a There were no treatment-related grade 4 or 5 events
b Preferred term: decreased appetite
c Preferred term: dysgeusia
d Preferred term: weight decreased
AEs A (20 mg) + C (AUC6) 
(n = 3), n
A (40 mg) + C (AUC6) 
(n = 9), n
Total (n = 12), n (%)
All grades Grade  3a All grades Grade  3a All grades Grade  3a
Any AE 3 0 9 3 12 (100) 3 (25)
Rash+ 2 0 7 1 9 (75) 1 (8)
Fatigue 3 0 5 1 8 (67) 1 (8)
Diarrhea 1 0 6 1 7 (58) 1 (8)
Nausea/vomiting+ 1 0 5 0 6 (50) 0
Anorexiab 1 0 3 0 4 (33) 0
Thrombocytopenia 1 0 2 0 3 (25) 0
Epistaxis 0 0 3 0 3 (25) 0
Oropharyngeal pain 0 0 3 0 3 (25) 0
Stomatitis 0 0 2 0 2 (17) 0
Rhinitis 0 0 2 0 2 (17) 0
Taste  changec 1 0 1 0 2 (17) 0
Dry skin 0 0 2 0 2 (17) 0
Weight  lossd 1 0 1 0 2 (17) 0
Nasal inflammation 0 0 2 0 2 (17) 0
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refractory NSCLC following ≥ 1 line of chemotherapy, 
and whose tumors had progressed after disease control 
of ≥ 12 weeks with erlotinib or gefitinib, and thereafter, 
afatinib. The combination of afatinib with paclitaxel sig-
nificantly improved tumor response and PFS compared with 
paclitaxel alone in patients who had EGFR tyrosine kinase 
inhibitor (TKI)-resistant (including afatinib) disease [19]. 
Conversely, in the phase III IMPRESS study, gefitinib plus 
cisplatin and pemetrexed in patients with EGFR mutation-
positive advanced NSCLC and acquired resistance to first-
line gefitinib did not prolong PFS in the overall population 
versus cisplatin plus pemetrexed [20]. Indeed, OS was infe-
rior in the experimental arm of this trial, although there was 
a suggestion of improved outcomes in patients lacking the 
T790M resistance mutation [21].
In the current study, the safety and clinical activity of 
two new afatinib combinations in patients with advanced 
solid tumors are presented. The RP2Ds of oral afatinib in 
these new combinations were defined as 40 mg/day with 
carboplatin AUC6, and 20 mg/day with carboplatin AUC5 
and paclitaxel 175 mg/m2. These regimens may be of poten-
tial interest for further study, for example, in patients with 
squamous NSCLC; in selected populations with EGFR 
mutations; and, particularly for the combination of afatinib 
and carboplatin, in elderly populations and patients with an 
ECOG PS of ≥ 2.
Table 4  Treatment-related AEs in at least 10% of total patients in the A/C/P arm
A/C/P afatinib plus carboplatin plus paclitaxel, AE adverse event, AUC5 area under the concentration–time curve of 5 mg/mL min, AUC6 area 
under the concentration–time curve of 6 mg/mL min
+ Grouped term (rash included reported preferred terms of rash, rash erythematous, rash pustular, dermatitis acneiform, skin fissures, blister and 
dermatitis; nausea/vomiting included reported preferred terms of nausea and vomiting)
a There were no treatment-related grade 4 or 5 events
b Preferred term: mucosal inflammation
c Preferred term: decreased appetite
d Preferred term: dysgeusia
AEs A (20 mg) + C 
(AUC6) + P (175 mg/
m2) (n = 7), n
A (20 mg) + C 
(AUC5) + P (175 mg/
m2) (n = 6), n
A (40 mg) + C 
(AUC5) + P (175 mg/
m2) (n = 5), n
A (30 mg) + C 
(AUC5) + P (175 mg/
m2) (n = 8), n
Total (n = 26), n (%)
All grades Grade 3a All grades Grade 3a All grades Grade 3a All grades Grade 3a All grades Grade  3a
Any AE 7 3 6 2 5 4 7 3 25 (96) 12 (46)
Diarrhea 6 1 6 0 5 0 6 0 23 (88) 1 (4)
Rash+ 2 0 5 0 5 0 7 0 19 (73) 0
Fatigue 5 1 4 0 5 2 4 0 18 (69) 3 (12)
Mucositisb 3 1 2 0 3 1 4 2 12 (46) 4 (15)
Anorexiac 4 0 1 0 3 0 2 0 10 (38) 0
Dry skin 2 0 2 0 1 0 3 0 8 (31) 0
Nausea/vomiting+ 4 0 0 0 1 0 3 0 8 (31) 0
Stomatitis 0 0 3 1 3 0 1 1 7 (27) 2 (8)
Thrombocytopenia 2 2 2 2 1 0 1 0 6 (23) 4 (15)
Peripheral neuropathy 1 0 2 0 0 0 3 0 6 (23) 0
Abdominal pain 4 0 0 0 1 0 1 0 6 (23) 0
Neutropenia 1 1 3 2 1 1 0 0 5 (19) 4 (15)
Epistaxis 2 0 1 0 1 0 1 0 5 (19) 0
Nasal inflammation 0 0 2 0 3 0 0 0 5 (19) 0
Alopecia 1 0 1 0 2 0 1 0 5 (19) 0
Arthralgia 1 0 1 0 1 0 2 0 5 (19) 0
Taste  changed 1 0 0 0 1 0 2 0 4 (15) 0
Constipation 1 0 1 0 1 0 1 0 4 (15) 0
Dyspepsia 2 0 0 0 0 0 2 0 4 (15) 0
Myalgia 1 0 3 0 0 0 0 0 4 (15) 0
Palmar–plantar 
erythrodysesthesia 
syndrome
0 0 1 0 0 0 2 0 3 (12) 0
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Table 5  Pharmacokinetic 
parameters for carboplatin 
(measured as total platinum) 
and paclitaxel in the presence 
and absence of afatinib at the 
RP2D
A afatinib, AE adverse event, AUC 0−23 area under the concentration–time curve of the analyte in plasma 
over 0–23 h, AUC 0−24 area under the concentration–time curve of the analyte in plasma over 0–24 h, AUC 
Ʈ,ss area under the concentration–time curve of the analyte in plasma over a dosing interval, tau, at steady 
state, AUC5 area under the concentration–time curve of 5 mg/mL min, AUC6 area under the concentra-
tion–time curve of 6  mg/mL  min, C carboplatin, Cmax maximum measured concentration of the analyte 
in plasma, Cmax,ss Cmax at steady state, gCV geometric coefficient of variation, gMean geometric mean, P 
paclitaxel, PK pharmacokinetic, RP2D recommended phase II dose
a Some patients who entered into the A (40 mg) + C (AUC6) cohort were not included in PK analyses in 
Cycle 2 due to AEs leading to treatment discontinuation, insufficient data availability for accurate PK eval-
uation or time violations in PK sampling
b One patient who entered into the A (20 mg) + C (AUC5) + P (175 mg/m2) cohort was not included in PK 
analyses in Cycle 1
c Additional patients who received A (30 mg) + C (AUC5) + P (175 mg/m2) in Cycle 1 were subsequently 
moved to the A (20 mg) + C (AUC5) + P (175 mg/m2) dose cohort for Cycle 2 and were included in the PK 
analyses
A (40 mg) + C (AUC6) A (20 mg) + C (AUC5) + P (175 mg/
m2)
Cycle 1 (− afatinib) Cycle 2 (+ afatinib) Cycle 1 (− afatinib) Cycle 2 
(+ afatinib)
gMean gCV, % gMean gCV, % gMean gCV, % gMean gCV, %
Afatinib
AUC Ʈ, ss, ng h/mL – n = 3a – n = 7c
465 91.8 326 60.4
Cmax,ss ng/mL – n = 3 – n = 7
44.2 9.76 18.3 52.6
Total platinum
AUC 0 − 24, ng h/mL n = 9 n = 6a n = 5b n = 8c
76,800 16.9 75,700 23.6 69,700 12.4 65,400 20.9
Cmax. ng/mL n = 9 n = 6 n = 5 n = 8
21,100 31.0 19,600 26.8 16,200 22.9 17,800 15.8
Paclitaxel
AUC 0 − 23, ng⋅h/mL – – n = 5b n = 8c
10,400 21.8 10,700 32.2
Cmax, ng/mL – – n = 5 n = 8
3710 23.4 3620 50.9
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